US FDA’s Inspection Volume Projected To Return To Normal Levels In FY 2022 As Backlog Looms
Additional hiring in FDA’s FY 2022 budget request also is expected to help address the inspections delayed by the coronavirus pandemic.
You may also be interested in...
CDER would receive $17m less in Senate appropriations bill compared to House veion, while CFSAN's total would be nearly $10m less. Overall, Senate bill includes around $50.4m less in funding for FDA than House bill.
CDER would lose the most money in the Senate appropriations bill compared to the House version, while CBER would see an increase.
The House Appropriations Committee also does not want the agency to become too dependent on alternative inspection tools.